BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ma W, Liu M, Liang F, Zhao L, Gao C, Jiang X, Zhang X, Zhan H, Hu H, Zhao Z. Cardiotoxicity of sorafenib is mediated through elevation of ROS level and CaMKII activity and dysregulation of calcium homoeostasis. Basic Clin Pharmacol Toxicol 2020;126:166-80. [DOI: 10.1111/bcpt.13318] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 7.7] [Reference Citation Analysis]
Number Citing Articles
1 Stępniak J, Krawczyk-lipiec J, Lewiński A, Karbownik-lewińska M. Sorafenib versus Lenvatinib Causes Stronger Oxidative Damage to Membrane Lipids in Noncancerous Tissues of the Thyroid, Liver, and Kidney: Effective Protection by Melatonin and Indole-3-Propionic Acid. Biomedicines 2022;10:2890. [DOI: 10.3390/biomedicines10112890] [Reference Citation Analysis]
2 Liang F, Zhang K, Ma W, Zhan H, Sun Q, Xie L, Zhao Z. Impaired autophagy and mitochondrial dynamics are involved in Sorafenib-induced cardiomyocyte apoptosis. Toxicology 2022;481:153348. [DOI: 10.1016/j.tox.2022.153348] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Zhuang J, Chen L, Li G, Xia L, Wu S, Leng J, Tao X, Hong J, Wu Y, Wang S, Yuan R. RCAN1 deficiency aggravates sepsis-induced cardiac remodeling and dysfunction by accelerating mitochondrial pathological fission. Inflamm Res 2022. [DOI: 10.1007/s00011-022-01628-5] [Reference Citation Analysis]
4 Li Y, Yan J, Zhao Q, Zhang Y, Zhang Y. ATF3 promotes ferroptosis in sorafenib-induced cardiotoxicity by suppressing Slc7a11 expression. Front Pharmacol 2022;13:904314. [DOI: 10.3389/fphar.2022.904314] [Reference Citation Analysis]
5 Liang Z, He Y, Hu X. Cardio-Oncology: Mechanisms, Drug Combinations, and Reverse Cardio-Oncology. IJMS 2022;23:10617. [DOI: 10.3390/ijms231810617] [Reference Citation Analysis]
6 Zaafar D, Khalil HMA, Rasheed RA, Eltelbany RFA, Zaitone SA. Hesperetin mitigates sorafenib-induced cardiotoxicity in mice through inhibition of the TLR4/NLRP3 signaling pathway. PLoS ONE 2022;17:e0271631. [DOI: 10.1371/journal.pone.0271631] [Reference Citation Analysis]
7 Terada CI, Onoue K, Fujii T, Itami H, Morita K, Uchiyama T, Takeda M, Nakagawa H, Nakano T, Baba Y, Amemiya K, Saito Y, Hatakeyama K, Ohbayashi C. Histopathological and epigenetic changes in myocardium associated with cancer therapy-related cardiac dysfunction. ESC Heart Fail 2022. [PMID: 35747987 DOI: 10.1002/ehf2.14034] [Reference Citation Analysis]
8 Tang X, Wang Z, Hu S, Zhou B. Assessing Drug-Induced Mitochondrial Toxicity in Cardiomyocytes: Implications for Preclinical Cardiac Safety Evaluation. Pharmaceutics 2022;14:1313. [DOI: 10.3390/pharmaceutics14071313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Scott SS, Greenlee AN, Matzko A, Stein M, Naughton MT, Zaramo TZ, Schwendeman EJ, Mohammad SJ, Diallo M, Revan R, Shimmin G, Tarun S, Ferrall J, Ho TH, Smith SA. Intracellular Signaling Pathways Mediating Tyrosine Kinase Inhibitor Cardiotoxicity. Heart Failure Clinics 2022. [DOI: 10.1016/j.hfc.2022.02.003] [Reference Citation Analysis]
10 Bouitbir J, Panajatovic MV, Krähenbühl S. Mitochondrial Toxicity Associated with Imatinib and Sorafenib in Isolated Rat Heart Fibers and the Cardiomyoblast H9c2 Cell Line. Int J Mol Sci 2022;23:2282. [PMID: 35216404 DOI: 10.3390/ijms23042282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Cadour F, Thuny F, Sourdon J. New Insights in Early Detection of Anticancer Drug-Related Cardiotoxicity Using Perfusion and Metabolic Imaging. Front Cardiovasc Med 2022;9:813883. [DOI: 10.3389/fcvm.2022.813883] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Zhou CC, He YQ, Qiu YS, Ni CX, Shen FM, Li DJ. Zinc supplementation ameliorates sorafenib-induced cognitive impairment through ROS/JNK signaling pathway. Biol Trace Elem Res 2022. [PMID: 35129807 DOI: 10.1007/s12011-022-03142-5] [Reference Citation Analysis]
13 Morciano G, Rimessi A, Patergnani S, Vitto VAM, Danese A, Kahsay A, Palumbo L, Bonora M, Wieckowski MR, Giorgi C, Pinton P. Calcium dysregulation in heart diseases: Targeting calcium channels to achieve a correct calcium homeostasis. Pharmacol Res 2022;177:106119. [PMID: 35131483 DOI: 10.1016/j.phrs.2022.106119] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
14 Khan SN, Neyaz MK. Cardiovascular disease in cancer survivors: Risk and management. Cardiovascular toxicity and therapeutic modalities targeting cardio-oncology 2022. [DOI: 10.1016/b978-0-323-90461-2.00003-1] [Reference Citation Analysis]
15 Kaur S. Cardiotoxic effects of tyrosine kinase inhibitors directed against VEGFR. Cardiovascular toxicity and therapeutic modalities targeting cardio-oncology 2022. [DOI: 10.1016/b978-0-323-90461-2.00008-0] [Reference Citation Analysis]
16 Bajpai R. Mitochondrial metabolism in progression of liver cancer. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma 2022. [DOI: 10.1016/b978-0-323-98806-3.00003-9] [Reference Citation Analysis]
17 Scott SS, Greenlee AN, Schwendeman EJ, Mohammad SJ, Naughton MT, Matzko A, Diallo M, Stein M, Revan R, Zaramo TZ, Shimmin G, Tarun S, Ferrall J, Ho TH, Smith SA. Intracellular Cardiac Signaling Pathways Altered by Cancer Therapies. Cardiovascular Signaling in Health and Disease 2022. [DOI: 10.1007/978-3-031-08309-9_4] [Reference Citation Analysis]
18 Zhou Y, Liao J, Mei Z, Liu X, Ge J. Insight into Crosstalk between Ferroptosis and Necroptosis: Novel Therapeutics in Ischemic Stroke. Oxid Med Cell Longev 2021;2021:9991001. [PMID: 34257829 DOI: 10.1155/2021/9991001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 17.0] [Reference Citation Analysis]
19 Fu X, Tang J, Wen P, Huang Z, Najafi M. Redox interactions-induced cardiac toxicity in cancer therapy. Arch Biochem Biophys 2021;708:108952. [PMID: 34097901 DOI: 10.1016/j.abb.2021.108952] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
20 Chen W, Deng M, Wang H, Wang Y, Zhou W, Yu T. ROS‑associated mechanism of different concentrations of pinacidil postconditioning in the rat cardiac Nrf2‑ARE signaling pathway. Mol Med Rep 2021;23:433. [PMID: 33846798 DOI: 10.3892/mmr.2021.12072] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
21 Chopra M, Sgro A, Norret M, Blancafort P, Iyer KS, Evans CW. SP94-Targeted Nanoparticles Enhance the Efficacy of Sorafenib and Improve Liver Cancer Cell Discrimination. ACS Appl Bio Mater 2021;4:1023-1029. [DOI: 10.1021/acsabm.0c01468] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
22 Pfeffer TJ, Pietzsch S, Hilfiker-Kleiner D. Common genetic predisposition for heart failure and cancer. Herz 2020;45:632-6. [PMID: 32542459 DOI: 10.1007/s00059-020-04953-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
23 Abdelgalil AA, Mohamed OY, Ahamad SR, Al-Jenoobi FI. The protective effect of losartan against sorafenib induced cardiotoxicity: Ex-vivo isolated heart and metabolites profiling studies in rat. Eur J Pharmacol 2020;882:173229. [PMID: 32505666 DOI: 10.1016/j.ejphar.2020.173229] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
24 Rodríguez-Hernández MA, de la Cruz-Ojeda P, López-Grueso MJ, Navarro-Villarán E, Requejo-Aguilar R, Castejón-Vega B, Negrete M, Gallego P, Vega-Ochoa Á, Victor VM, Cordero MD, Del Campo JA, Bárcena JA, Padilla CA, Muntané J. Integrated molecular signaling involving mitochondrial dysfunction and alteration of cell metabolism induced by tyrosine kinase inhibitors in cancer. Redox Biol 2020;36:101510. [PMID: 32593127 DOI: 10.1016/j.redox.2020.101510] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 13.0] [Reference Citation Analysis]
25 Pushparaji B, Marmagkiolis K, Miller CK, Aziz MK, Balanescu DV, Donisan T, Palaskas N, Kim P, Lopez-mattei J, Cilingiroglu M, Hassan SA, Iliescu CA. State-of-the-art Review: Interventional Onco-Cardiology. Curr Treat Options Cardio Med 2020;22. [DOI: 10.1007/s11936-020-00809-x] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]